Successfully merged with Tango Therapeutics, Inc. • Now trading as TNGX
SPAC Overview
$167M
IPO Size
$167M
Trust (as of 2021-06-30)
Completed
Current Status
2020
IPO Year
Timeline Progress
About
BCTG Acquisition Corp. is a blank-check company seeking to complete a merger or other business combination. It intends to focus on innovative biotechnology companies in North America and Europe.
Investment Focus
Biopharmaceuticals
Geographic Focus
North America, Europe
The terms and the filing trail behind BCTG Acquisition Corp.
What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.
- Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
- Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
- The full 8-K lifecycle timeline, each event linked to its filing
- Price history across the unit, share and warrant tickers
- Follow it, and see it change on your watchlist
SPAC Team
Sponsors
Leadership
Aaron I. Davis
Chairman of the Board of Directors, Chief Executive Officer, Chief Financial Officer, Director, Treasurer
Alexis Borisy
Chair of the Board of Directors
Barbara Weber M.D.
Chief Executive Officer, Director, President, President, Chief Executive Officer and Chairperson
Christopher David Fuglesang
Chief Operating Officer, Director, President, Secretary
Daniel Beckman
Chief Financial Officer
Michael Beauchamp
Chief Financial Officer, Director, Treasurer
Alan Huang Ph.D.
Chief Scientific Officer
Andrew Ruel Ellis
Chief Operating Officer, Director, Secretary
Carole L. Nuechterlein
Director
Charles M. Baum
Director
Jamie Christensen
Director
Lesley Ann Calhoun
Director
Mace Rothenberg M.D.
Director
Malte Peters M.D.
Director
Reid M. Huber
Director
Richard A. Heyman
Director
Underwriters
Extended Team Information
The team draws on Boxer Capital, a private biopharmaceutical investment firm with experience investing in therapeutics, including targeted oncology, and includes company founders with biotechnology investing backgrounds plus directors with expertise in oncology drug discovery, development, regulation and company leadership.
Stock Performance
TNGX
Trading Symbol
First Trade
2020-09-04
$10.33
At Merger
2021-08-12
$9.56
-7%
6 Months Post-Merger
2022-02-10
$9.38
-2%
1 Year Post-Merger
2022-08-15
$5.39
-44%
2 Years Post-Merger
2023-08-14
$6.99
-27%
Current Price
2026-10-02
$23.24
+125%
Key Information
IPO Date
2020-09-04
Total Redemptions
$11.1M
PIPE
$186M
State of Incorporation
DE
SIC
6770
Completion Date
2021-08-10
Merger Target
Tango Therapeutics, Inc.
SPAC Ticker
BCTG
Merged Ticker
TNGX